ライフサイエンスコーパス: cervical intraepithelial neoplasia

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 d anogenital intraepithelial neoplasias (eg, cervical intraepithelial neoplasia).

2 of 345 women who were at risk of developing cervical intraepithelial neoplasia.

3 of both HPV-16 infection and HPV-16-related cervical intraepithelial neoplasia.

4 ssociated virus influenced the production of cervical intraepithelial neoplasia.

5 tion of women before and after treatment for cervical intraepithelial neoplasia.

6 h abnormal Papanicolou smears, indicative of cervical intraepithelial neoplasia.

7 and treating premalignant cervical lesions (cervical intraepithelial neoplasia 2+ [CIN2+]) is an eff

8 hich cause 70% of cervical cancer and 50% of cervical intraepithelial neoplasia 2/3 and adenocarcinom

9 Development of cervical intraepithelial neoplasia 2/3 was rare in women

10 s limited benefit to reduce the incidence of cervical intraepithelial neoplasia 3 and no benefit to r

11 mary-screening algorithm found more disease (cervical intraepithelial neoplasia 3 or worse [CIN3+]) a

12 35; 95% CI, 1.67 to 3.31); grade 2 or higher cervical intraepithelial neoplasia, 6.9% vs. 3.4% (hazar

13 Biopsy tissue was evaluated for cervical intraepithelial neoplasia and analyzed for HPV-

14 ncer-derived cell lines and human tissues of cervical intraepithelial neoplasia and cervical cancer.

15 stion: Does local conservative treatment for cervical intraepithelial neoplasia and early invasive ce

16 ansmitted pathogen capable of giving rise to cervical intraepithelial neoplasia and invasive carcinom

17 helium is low but increases significantly in cervical intraepithelial neoplasia and invasive squamous

18 Conservative methods to treat cervical intraepithelial neoplasia and microinvasive cer

19 isk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervica

20 human carcinogenesis including primary human cervical intraepithelial neoplasias and HPV positive hea

21 (human papillomavirus-16 seropositivity with cervical intraepithelial neoplasia, and EBV responses wi

22 termined that TopBP1 levels are increased in cervical intraepithelial neoplasias as well as cervical

23 oteins resulted in development of high-grade cervical intraepithelial neoplasia, but not frank cervic

24 atients who have been treated for high-grade cervical intraepithelial neoplasia (CIN grade >=2) are a

25 e reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocar

26 fidence interval [CI], 5.1% to 28.7%) and of cervical intraepithelial neoplasia (CIN) 1-3 or adenocar

27 previously used this probe set to show that cervical intraepithelial neoplasia (CIN) 2 and CIN3 lesi

28 PV of abnormal cervical cytology for risk of cervical intraepithelial neoplasia (CIN) 2 or more sever

29 papillomavirus (HPV) during the follow-up of cervical intraepithelial neoplasia (CIN) 2/3 after biops

30 cterize the local immune microenvironment in cervical intraepithelial neoplasia (CIN) 2/3 and determi

31 Case patients (n = 124) had cervical intraepithelial neoplasia (CIN) 3 or 2.

32 The authors assessed risk factors for cervical intraepithelial neoplasia (CIN) among southwest

33 ct data about test performance for detecting cervical intraepithelial neoplasia (CIN) and cancer and

34 e frequently diagnosed with higher grades of cervical intraepithelial neoplasia (CIN) and cancer, as

35 n strongly implicated in the pathogenesis of cervical intraepithelial neoplasia (CIN) and cervical ca

36 rogression of HPV-related disease, including cervical intraepithelial neoplasia (CIN) and invasive ce

37 nown about the long-term yield of high-grade cervical intraepithelial neoplasia (CIN) and the influen

38 Conservative outpatient therapy for cervical intraepithelial neoplasia (CIN) by ablative or

39 PV), but the correlation between BV, HPV and cervical intraepithelial neoplasia (CIN) development is

40 Over 60,000 women are treated for cervical intraepithelial neoplasia (CIN) each year in En

41 gated 12 high-grade and 4 low-grade cases of cervical intraepithelial neoplasia (CIN) for LOH after l

42 ions occur in CC progression, we analysed 33 cervical intraepithelial neoplasia (CIN) for LOH.

43 rd deviation]) with histologically confirmed cervical intraepithelial neoplasia (CIN) found on smear

44 ogy, 137 cases with histologically confirmed cervical intraepithelial neoplasia (CIN) grade 1 (CIN1),

45 The number of cases of cervical intraepithelial neoplasia (CIN) grade 2 and 3 d

46 rocedure (LEEP) for histologically confirmed cervical intraepithelial neoplasia (CIN) grade 2 or high

47 we determined the cumulative 2-year risks of cervical intraepithelial neoplasia (CIN) grade 2 or more

48 colposcopy; and short term risk of detecting cervical intraepithelial neoplasia (CIN) grade 2 or wors

49 ection, the 36-month cumulative incidence of cervical intraepithelial neoplasia (CIN) grade 2 was 20.

50 Cases were defined as women classified with cervical intraepithelial neoplasia (CIN) grade 2+ (CIN2+

51 es with 40 or more women living with HIV and cervical intraepithelial neoplasia (CIN) grade 2+ were i

52 e squamous intraepithelial lesions (HSIL) or cervical intraepithelial neoplasia (CIN) grade 2/3 lesio

53 n in women with invasive cervical cancer and cervical intraepithelial neoplasia (CIN) grade 3 with th

54 We analyzed data on cervical intraepithelial neoplasia (CIN) grades 2-3 and

55 sk of relapse after treatment for high-grade cervical intraepithelial neoplasia (CIN) has important c

56 reening history and histologically confirmed cervical intraepithelial neoplasia (CIN) in 2.5 years af

57 Increased risk for cervical intraepithelial neoplasia (CIN) in human immuno

58 sion along the entire neoplastic spectrum of cervical intraepithelial neoplasia (CIN) in the process

59 for oncogenic human papillomaviruses (HPVs), cervical intraepithelial neoplasia (CIN) is common, and

60 vaccine efficacy of 100% (42.4-100) against cervical intraepithelial neoplasia (CIN) lesions associa

61 Women who smoke and have a history of cervical intraepithelial neoplasia (CIN) or cervical can

62 ce; squamous intraepithelial lesion (SIL) or cervical intraepithelial neoplasia (CIN) prevalence, inc

63 morbidity of different treatment methods for cervical intraepithelial neoplasia (CIN) remains unclear

64 for squamous intraepithelial lesion (SIL) or cervical intraepithelial neoplasia (CIN) removes or abla

65 To determine the population-based cervical intraepithelial neoplasia (CIN) trends when adj

66 aseline prognostic test to ascertain whether cervical intraepithelial neoplasia (CIN) will regress or

67 cervical specimens, including 38 normal, 52 cervical intraepithelial neoplasia (CIN), and 68 cervica

68 ectrum of cervical disease: cervical cancer, cervical intraepithelial neoplasia (CIN), and HPV infect

69 ith healthy, human papilloma virus (HPV) +/- cervical intraepithelial neoplasia (CIN), or cervical ca

70 d 5 (56%) of 9 HPV-16-positive women without cervical intraepithelial neoplasia (CIN), respectively.

71 Four PV types were associated with cervical intraepithelial neoplasia (CIN), which resemble

72 han cytology for the detection of high-grade cervical intraepithelial neoplasia (CIN).

73 ervical cancer and its precursor, high-grade cervical intraepithelial neoplasia (CIN).

74 ected at the time of diagnosis of high-grade cervical intraepithelial neoplasia (CIN).

75 ation between human papillomavirus (HPV) and cervical intraepithelial neoplasia (CIN).

76 ytology for the identification of high-grade cervical intraepithelial neoplasia (CIN).

77 women were followed semiannually for HPV and cervical intraepithelial neoplasia (CIN).

78 us (HPV) types in a broader group that cause cervical intraepithelial neoplasia (CIN).

79 n, human papillomavirus (HPV) infection, and cervical intraepithelial neoplasia (CIN); however, causa

80 apillomaviruses (HPV) results in precancers [cervical intraepithelial neoplasia (CIN)] and cancers ne

81 sue specimens with normal cervix (20 cases), cervical intraepithelial neoplasia (CIN; CIN 1, 27 cases

82 ush specimens from 149 women with high-grade cervical intraepithelial neoplasias (CIN II-CIN III), 17

83 from preinvasive dysplastic lesions, termed cervical intraepithelial neoplasias (CIN), grades I-III.

84 revealing intense angiogenesis in high-grade cervical intraepithelial neoplasias (CIN-3) and carcinom

85 gnificantly increased with disease severity (cervical intraepithelial neoplasia [CIN] 3, 17.9% [+/-7.

86 ade cervical lesions on histology (less than cervical intraepithelial neoplasia [CIN] grade 2) were r

87 Cs and their accompanying precursor lesions (cervical intraepithelial neoplasia, CIN; n = 40) and nor

88 hosphorylated STAT3 increased from low-grade cervical intraepithelial neoplasia (CIN1) to precancerou

89 mples spanning normalcy, increasingly severe cervical intraepithelial neoplasia (CIN1- CIN3), and cer

90 (HIV) plasma viral load (PVL) on high-grade cervical intraepithelial neoplasia (CIN2+) detection at

91 eck with HC2 for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a total of

92 cific than cytology for detecting high-grade cervical intraepithelial neoplasia (CIN2+).

93 d cytology for histology-verified high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) at base

94 on between persistent HPV DNA and high-grade cervical intraepithelial neoplasia (CIN2-3), high-grade

95 the time span of progression from high-grade cervical intraepithelial neoplasia (CIN2/3) to invasive

96 tests for the ability to predict high-grade cervical intraepithelial neoplasias (CIN2 or worse) in c

97 Overall, 28 high-grade cervical intraepithelial neoplasia (CIN3) cases were det

98 d cervical carcinoma in situ, namely grade 3 cervical intraepithelial neoplasia (CIN3), registrations

99 lative incidence rates (CIRs) of >/= grade 3 cervical intraepithelial neoplasia (CIN3+) or cancer for

100 Cervical dysplastic lesions called cervical intraepithelial neoplasias (CINs) need be treat

101 e is no prognostic test to ascertain whether cervical intraepithelial neoplasias (CINs) regress or pr

102 In cervical intraepithelial neoplasias from patients who we

103 data on screening strategies for identifying cervical intraepithelial neoplasia grade >= 2 in healthy

104 s (HSILs) diagnosed cytologically; 1198 with cervical intraepithelial neoplasia grade 1 (CIN1), 456 w

105 layers in eight of nine cases of HPV16/18(+) cervical intraepithelial neoplasia grade 1 (CIN1); howev

106 s with precancer risks of less than 25% (eg, cervical intraepithelial neoplasia grade 1 [CIN1] or his

107 cacy against 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or greater (C

108 associated with older age and a diagnosis of cervical intraepithelial neoplasia grade 1 or greater.

109 cacy against 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or higher (CI

110 Histological diagnosis of cervical intraepithelial neoplasia grade 2 (CIN2) has tr

111 Active surveillance for cervical intraepithelial neoplasia grade 2 (CIN2) is bei

112 d for each channel based on the detection of cervical intraepithelial neoplasia grade 2 (CIN2) or gre

113 detection, clinical performance in detecting cervical intraepithelial neoplasia grade 2 (CIN2) or mor

114 histologic diagnosis of controls (less than cervical intraepithelial neoplasia grade 2 [<CIN2]) or c

115 th highest viral load, which varied by type (cervical intraepithelial neoplasia grade 2 [CIN2] for HP

116 prevent cancer by detection and treatment of cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3)

117 history of a high-grade precancerous lesion (cervical intraepithelial neoplasia grade 2 or 3) or cerv

118 re incidence of high-grade cervical disease (cervical intraepithelial neoplasia grade 2 or 3, adenoca

119 riage Study, we selected women with incident cervical intraepithelial neoplasia grade 2 or grade 3 (C

120 Seventy WLWH had histologically-determined cervical intraepithelial neoplasia grade 2 or greater (C

121 Cumulative risks of cervical intraepithelial neoplasia grade 2 or greater (C

122 luated against 6-month persistent infection, cervical intraepithelial neoplasia grade 2 or greater (C

123 Sensitivity of detecting cervical intraepithelial neoplasia grade 2 or greater in

124 of these types) were informative to predict cervical intraepithelial neoplasia grade 2 or greater.

125 n papillomavirus (hrHPV) after treatment for cervical intraepithelial neoplasia grade 2 or higher (CI

126 ry outcome measure was risk of recurrence of cervical intraepithelial neoplasia grade 2 or higher (CI

127 ficity of the Xpert HPV for the detection of cervical intraepithelial neoplasia grade 2 or higher (CI

128 cervicovaginal samples for the detection of cervical intraepithelial neoplasia grade 2 or higher (CI

129 lasia grades 2/3 and adenocarcinoma in situ (cervical intraepithelial neoplasia grade 2 or higher [CI

130 thelial neoplasia grade 2 [<CIN2]) or cases (cervical intraepithelial neoplasia grade 2 or higher [CI

131 hen compared to histopathologic diagnosis of cervical intraepithelial neoplasia grade 2 or more sever

132 The sensitivity of Xpert for cervical intraepithelial neoplasia grade 2 or more sever

133 , number of doses administered, diagnoses of cervical intraepithelial neoplasia grade 2 or worse (CIN

134 vs. 92.7%) than cytology with HPV triage for cervical intraepithelial neoplasia grade 2 or worse (CIN

135 he results of clinician-collected sample and cervical intraepithelial neoplasia grade 2 or worse (CIN

136 19.1% and 12.9% had histologically-confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN

137 d the age where risk of being diagnosed with cervical intraepithelial neoplasia grade 2 or worse (CIN

138 med to evaluate HPV vaccine efficacy against cervical intraepithelial neoplasia grade 2 or worse (CIN

139 prevention have used the disease endpoint of cervical intraepithelial neoplasia grade 2 or worse (CIN

140 vaccine for preventing HPV 16/18-associated cervical intraepithelial neoplasia grade 2 or worse (CIN

141 nual reading for the detection of underlying cervical intraepithelial neoplasia grade 2 or worse (CIN

142 6/18 combination predicted 69.4% of incident cervical intraepithelial neoplasia grade 2 or worse comp

143 difference in vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 2 or worse in H

144 and PATRICIA criteria, VE estimates against cervical intraepithelial neoplasia grade 2 or worse, reg

145 1 and 2.4 colposcopy referrals to detect one cervical intraepithelial neoplasia grade 2 or worse, res

146 of the Onclarity assay for the detection of cervical intraepithelial neoplasia grade 2+ (CIN2+) and

147 Both assays detected >/=91.7% of cervical intraepithelial neoplasia grade 2+ (CIN2+) lesi

148 V infections, anogenital wart diagnoses, and cervical intraepithelial neoplasia grade 2+ (CIN2+) to s

149 As a result, we identified 90 women with cervical intraepithelial neoplasia grade 2+ (CIN2+), inc

150 lial neoplastic lesions and invasive cancer (cervical intraepithelial neoplasia grade 2+ [CIN2+]) com

151 We assessed if risk of developing cervical intraepithelial neoplasia grade 2/3 (CIN2/3) or

152 -grade squamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3])

153 d biopsies from patients with HPV-associated cervical intraepithelial neoplasia grade 2/3 and murine

154 ments made on normal tissue and that showing cervical intraepithelial neoplasia grade 2/3; the area u

155 d lowest specificity (46%-54%) for consensus cervical intraepithelial neoplasia grade 3 (CIN 3).

156 ion between the HPV DNA load and the risk of cervical intraepithelial neoplasia grade 3 (CIN-3) diffe

157 ignificant reductions in cervical cancer and cervical intraepithelial neoplasia grade 3 (CIN3) after

158 ublished estimates of 3- and 5-year risks of cervical intraepithelial neoplasia grade 3 (CIN3) among

159 were most likely to persist and progress to cervical intraepithelial neoplasia grade 3 (CIN3) and ca

160 r this substudy was histologically confirmed cervical intraepithelial neoplasia grade 3 (CIN3) or wor

161 ify women at high risk of cervical cancer or cervical intraepithelial neoplasia grade 3 (CIN3) or wor

162 and premalignancies in women diagnosed with cervical intraepithelial neoplasia grade 3 (CIN3).

163 16 and/or HPV18 (HPV16/18) detected 93.4% of cervical intraepithelial neoplasia grade 3 and 100% of i

164 13 oncogenic HPV types, for the detection of cervical intraepithelial neoplasia grade 3 and cancer (C

165 The baseline specimens from 482 cases of cervical intraepithelial neoplasia grade 3 or cancer (CI

166 er and its immediate precancerous precursor, cervical intraepithelial neoplasia grade 3 or carcinoma

167 Similar results were observed for cervical intraepithelial neoplasia grade 3 or higher (CI

168 The primary endpoint was cervical intraepithelial neoplasia grade 3 or more sever

169 igated the timing of diagnosis of histologic cervical intraepithelial neoplasia grade 3 or worse (CIN

170 he primary outcome was the detection rate of cervical intraepithelial neoplasia grade 3 or worse (CIN

171 elial neoplasia grade 2 or worse (CIN2+) and cervical intraepithelial neoplasia grade 3 or worse (CIN

172 ed as histopathologically confirmed CIN2+ or cervical intraepithelial neoplasia grade 3 or worse asso

173 ral persistence and/or precancer and cancer [cervical intraepithelial neoplasia grade 3+ (CIN3+)].

174 cimens from women with a diagnosis of CIN3+ (cervical intraepithelial neoplasia grade 3+ or cervical

175 uding 54 women with histologically confirmed cervical-intraepithelial neoplasia grade 2 or worse [>or

176 d with tests for hrHPV and HPV 16/18 to find cervical intraepithelial neoplasia (grade >/=2 [CIN2+] o

177 d with tests for hrHPV and HPV 16/18 to find cervical intraepithelial neoplasia (grade >/=2 [CIN2+] o

178 rmined significance or greater (ASCUS+), and cervical intraepithelial neoplasia grades 1/2 or greater

179 mavirus 31 (HPV31) DNA loads and the risk of cervical intraepithelial neoplasia grades 2 and 3 (CIN2-

180 Cervical cancer and its obligate precursors, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/

181 We describe changes in rates of cervical intraepithelial neoplasia grades 2, 3 and adeno

182 We analyzed data on cervical intraepithelial neoplasia grades 2-3 and adenoc

183 53.3% (95% CI = 37.9 to 68.3) for diagnosing cervical intraepithelial neoplasia grades 2/3 (CIN2/3) o

184 icut (CT) implemented mandatory reporting of cervical intraepithelial neoplasia grades 2/3 and adenoc

185 f the spinous cells in benign lesions and in cervical intraepithelial neoplasia grades I and II.

186 Methods used to diagnose and treat cervical intraepithelial neoplasia have important potent

187 cip1 antigen-positive cells were sporadic in cervical intraepithelial neoplasia III and rare and foca

188 Twenty per cent of cervical intraepithelial neoplasias-III (CIN-III) progre

189 tudies revealed the presence of condyloma or cervical intraepithelial neoplasia in 16 women (24.6%) a

190 l lesions was decoded from five grade 2 or 3 cervical intraepithelial neoplasia lesion (CIN2/3) sampl

191 Cervical intraepithelial neoplasia lesions of grade two

192 All nine cases of HPV-16-related cervical intraepithelial neoplasia occurred among the pl

193 number of diagnoses of anogenital warts and cervical intraepithelial neoplasia of grade 2 or 3 and c

194 number of diagnoses of anogenital warts and cervical intraepithelial neoplasia of grade 2 or 3 and c

195 ure (ie, incident persistent qHPV infection, cervical intraepithelial neoplasia of grade 2 or higher

196 cross-sectional clinical accuracy to detect cervical intraepithelial neoplasia of grade 2 or worse (

197 ative tests, the prevalence of biopsy-proven cervical intraepithelial neoplasia of grade 2 was 0.028

198 d in a good performance for the detection of cervical intraepithelial neoplasia of grade 3 or higher,

199 reening were calculated for the detection of cervical intraepithelial neoplasia of grade 3 or higher.

200 currence of residual or recurrent high-grade cervical intraepithelial neoplasia of grade two or worse

201 development toward clinical testing against cervical intraepithelial neoplasia or carcinoma.

202 All the excisional procedures to treat cervical intraepithelial neoplasia present similar pregn

203 ciated with cervical lesion progression from cervical intraepithelial neoplasia stage 1 (CIN1, low gr

204 There was no link with cervical intraepithelial neoplasia status and detection

205 nalysis to participants without a history of cervical intraepithelial neoplasia treatment.

206 However, high-grade cervical intraepithelial neoplasia was found more freque

207 Lynch syndrome, clonal hematopoiesis, and cervical intraepithelial neoplasia which also serve as m